| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK20 |
| Uniprot No | Q8IZL9 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-346aa |
| 氨基酸序列 | MDQYCILGRI GEGAHGIVFK AKHVETGEIV ALKKVALRRL EDGFPNQALR EIKALQEMED NQYVVQLKAV FPHGGGFVLA FEFMLSDLAE VVRHAQRPLA QAQVKSYLQM LLKGVAFCHA NNIVHRDLKP ANLLISASGQ LKIADFGLAR VFSPDGSRLY THQVATRWYR APELLYGARQ YDQGVDLWSV GCIMGELLNG SPLFPGKNDI EQLCYVLRIL GTPNPQVWPE LTELPDYNKI SFKEQVPMPL EEVLPDVSPQ ALDLLGQFLL YPPHQRIAAS KALLHQYFFT APLPAHPSEL PIPQRLGGPA PKAHPGPPHI HDFHVDRPLE ESLLNPELIR PFILEG |
| 预测分子量 | 38,6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK20重组蛋白的假设参考文献示例(仅供参考，具体文献需通过学术数据库验证)：
---
1. **标题**: *CDK20 promotes hepatocellular carcinoma metastasis via interaction with β-catenin*
**作者**: Li et al.
**摘要**: 研究通过重组CDK20蛋白的体外激酶实验，揭示其通过磷酸化β-catenin增强Wnt信号通路，促进肝癌细胞侵袭。
2. **标题**: *Expression and functional characterization of recombinant human CDK20 in E. coli*
**作者**: Smith et al.
**摘要**: 报道在大肠杆菌中高效表达可溶性CDK20重组蛋白，并验证其激酶活性及对细胞周期蛋白的调控作用。
3. **标题**: *CDK20 as a novel therapeutic target in pancreatic cancer: Insights from recombinant protein-based drug screening*
**作者**: Zhang et al.
**摘要**: 利用重组CDK20蛋白筛选小分子抑制剂，发现特定化合物可抑制其活性并延缓胰腺癌细胞增殖。
4. **标题**: *Structural basis of CDK20 activation by cyclin binding*
**作者**: Wang et al.
**摘要**: 通过重组CDK20与细胞周期蛋白的复合物晶体结构解析，阐明其激活机制及底物识别位点。
---
建议通过 **PubMed** 或 **Google Scholar** 搜索关键词“CDK20 recombinant protein”“CCRK expression”获取真实文献。
CDK20 (Cyclin-Dependent Kinase 20), also known as CCRK (Cell Cycle-Related Kinase), is a serine/threonine protein kinase belonging to the CDK family, which plays pivotal roles in regulating cell cycle progression and transcriptional modulation. Unlike canonical CDKs (e.g., CDK1. CDK4/6), CDK20 exhibits unique functional characteristics. It forms a complex with cyclin Y or cyclin L and phosphorylates critical substrates such as RNA polymerase II, thereby influencing transcription elongation and cell cycle transitions. Structurally, CDK20 retains a conserved kinase domain with ATP-binding and catalytic sites, but its regulatory mechanisms diverge from other CDKs due to distinct cyclin interactions and substrate specificity.
CDK20 has garnered attention for its oncogenic potential. Overexpression of CDK20 is observed in multiple cancers, including hepatocellular carcinoma, colorectal cancer, and glioblastoma, where it promotes tumor cell proliferation, survival, and metastasis by activating Wnt/β-catenin, PI3K/AKT, or other signaling pathways. Its role in driving cell cycle progression and transcriptional dysregulation makes it a potential therapeutic target. However, its physiological functions in normal tissues remain less understood, though studies suggest involvement in ciliogenesis and neuronal development.
Recombinant CDK20 proteins are engineered using expression systems (e.g., E. coli, insect cells) to retain kinase activity for biochemical studies. These proteins enable in vitro analysis of CDK20-cyclin interactions, substrate phosphorylation, and inhibitor screening. Researchers utilize recombinant CDK20 to explore its structural biology, develop targeted therapies, and validate diagnostic biomarkers. Challenges in production include maintaining proper folding and post-translational modifications critical for functionality. Despite these hurdles, recombinant CDK20 remains a vital tool for unraveling its pathological mechanisms and advancing precision oncology.
×
